

5 January 2024

Specified Drug Treatments for Various Conditions

1. How many patients have been treated (for any condition) in the last 4 months with:

Dermatology:

- **Benralizumab** <5
- **Dupilumab** 153
- **Omalizumab** 31
- **Reslizumab** <5
- **Mepolizumab** <5
- **Tezepelumab** <5

Use of <5 (less than five): We are unable to provide an exact figure where numbers are very low, i.e. <5 as this information would reduce numbers to discoverable limits, where the patients could be identifiable.

The information is exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

Adult Respiratory:

Benralizumab	123 (plus <5 waiting to start)
Dupilumab	55 (plus 18 waiting to start / approval from Board)
Omalizumab	21
Reslizumab	0 (drug no longer available)
Mepolizumab	258 (plus 12 waiting to start)
Tezepelumab	5 (plus 12 waiting to start / approval from Board)

Paediatric Respiratory:

- **Benralizumab** 0
- **Dupilumab** <5
- **Omalizumab** 0
- **Reslizumab** 0
- **Mepolizumab** <5
- **Tezepelumab** 0

Immunology:

Omalizumab:	177
Dupilumab:	16

5 January 2024

2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age groups:

Dermatology:

- **Age 6 – 11:** 12
- **Age 12 – 17:** 19
- **Age 18 and above:** 153

Adult Respiratory:

- **Age 6 – 11:** 0
- **Age 12 – 17:** 0
- **Age 18 and above:** 462

Paediatric Respiratory:

- **Age 6 – 11:** 0
- **Age 12 – 17:** <5
- **Age 18 and above:** 0

Immunology:

- **Age 6 – 11:** <5
- **Age 12 – 17:** <5
- **Age 18 and above:** 187

3. How many patients have been treated in the last 4 months by the Respiratory Medicines Department ONLY with:

Adult Respiratory:

- **Dupilumab** 55
- **Omalizumab** 21

Paediatric Respiratory:

- **Dupilumab** <5
- **Omalizumab** 0